## Beneficiary Advisory Panel Handout Uniform Formulary Decisions 08 Jan 2009

**PURPOSE:** The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

Table 1: Uniform Formulary Recommendations from the November 2008 DoD P&T Committee Meeting

UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?			
	Nasal Allergy Drugs					
	Azelastine (Astelin)	nasal inhaler	No			
	Flunisolide (Nasarel, generics)	nasal inhaler	Yes			
Formulary	Fluticasone propionate (Flonase, generics)	nasal inhaler	Yes			
	Mometasone (Nasonex)	nasal inhaler	No			
	Ipratropium (Atrovent)	nasal inhaler	Yes			
	Beclomethasone (Beconase AQ)	nasal inhaler	No			
	Budesonide (Rhinocort Aqua)	nasal inhaler	No			
Non-Formulary	Ciclesonide (Omnaris)	nasal inhaler	No			
Non-Formulary	Fluticasone furoate (Veramyst)	nasal inhaler	No			
	Triamcinolone (Nasacort AQ)	nasal inhaler	No			
	Olopatadine (Patanase)	nasal inhaler	No			
Recommended implementation period	60 d	ays				
	Short-Acting Beta Agonists (SA	ABAs)				
	Albuterol solution (Accuneb, generics)	inhalation solution	Yes			
	Levalbuterol solution (Xopenex)	inhalation solution	No			
Formulary	Albuterol inhaler (Proair, Proventil HFA, Ventolin HFA)	metered dose inhaler	No			
	Levalbuterol inhaler (Xopenex)	metered dose inhaler	No			
Non-Formulary*	Metaproterenol solution (Alupent, generics)	inhalation solution	Yes			
non i omidiai y	Pirbuterol inhaler (Maxair)	metered dose inhaler	No			
Recommended implementation period 60 days						

<sup>\*:</sup> Note regarding non-formulary SABAs: Generic formulations of albuterol metered dose inhaler and metaproterenol metered dose inhaler (Alupent) will no longer be marketed after 31 Dec 2008, due to ban of chlorofluorocarbon propellant

Figure 1: Nasal Allergy Drugs

## **Nasal Allergy Drug Utilization**

## MHS Utilization of Nasal Allergy Drugs




Figure 2: Nasal Allergy Drugs

## Nasal Allergy Drug Utilization MHS without Flonase




Figure 3: Short-Acting Beta Agonists – Metered Dose Inhaler





Figure 4: Short-Acting Beta Agonists – Inhalation Solution



**Table 6: Uniform Formulary Implementation Plan Summary** 

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	iaries Affe	cted by	Implementation Plan	Justification	Step
Weeting	Class	Non-i orinitially medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date		Therapy
Nov 08	Inhaled Short Acting Beta Agonist	<ul> <li>Metaproterenol inhaled solution</li> <li>Pirbuterol CFC MDI (Maxair)</li> </ul>	1,278	44	1,002	232	60	Small number of beneficiaries affected	No
Nov 08	Nasal Allergy Drugs	<ul> <li>Beclomethasone (Beconase AQ)</li> <li>Budesonide (Rhinocort AQ)</li> <li>Ciclesonide (Omnaris)</li> <li>Fluticasone Furoate (Veramyst)</li> <li>Triamcinolone (Nasacort AQ)</li> <li>Olopatadine (Patanase)</li> </ul>	34,271	440	27,017	6,814	60	Nasal corticosteroids reviewed Nov 05, no changes to UF other than Patanase and Omnaris made non-formulary (1,794 users)	No
Aug 08	Self-Monitoring Blood Glucose System Test Strips	<ul> <li>One Touch (for One Touch Ultra 2, Ultra Mini, and Ultra Smart meters)</li> <li>TrueTrack strips (for TrueTrack meter)</li> <li>Accu-chek Comfort Curve strips (for Accu-chek Advantage meter)</li> <li>Accu-chek Compact Plus drum (for Accu-check Compact Plus meter)</li> <li>Accu-chek Simplicity, Ascensia Autodisk, Ascensia Breeze 2, Ascensia Elite, Assure, Assure 3, Assure II, Assure Pro, Bd Test Strips, Chemstrip Bg, Control AST, Dextrostix Reagent, Easygluco, Easypro, Fast Take, Freestyle test strips (other than Freestyle Lite), Glucofilm, Glucolab, Glucometer Dex, Glucometer Elite, Glucose Test Strip, Glucostix, Optium, Precision Pcx, Precision Pcx Plus, Precision Q-I-D, Precision Sof-Tact, Prestige Smart System, Prodigy, Quicktek, Sidekick, Sof-Tact, Surestep, Surestep Pro, Test Strip,</li> </ul>	58,142	12,271	33,658	12,231	120	Allow time for patients to receive new meters	No

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	ciaries Affec	cted by	Implementation Plan	Justification	Step
Meeting	Class	Non-romulary medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justilication	Therapy
		Relion Ultima, Uni-Check  Plus all other store/private label brand strips not included on Uniform Formulary (see the BCF/ECF column)							
Aug 08	Overactive Bladder Drugs	<ul><li>Tolterodine IR (Detrol)</li><li>Trospium IR (Sanctura)</li></ul>	4,215	235	1,210	2,770	90	Typical 90-day implementation period	No
		Desvenlafaxine (Pristiq)	745	0	694	51	60	New drug in already reviewed class; low utilization	No
Aug 08	Antidepressant – 1s	Original Meeting Nov 05     paroxetine HCl CR (Paxil)     fluoxetine 90 mg for weekly administration (Prozac Weekly)     fluoxetine in special packaging for PMDD (Sarafem)     escitalopram (Lexapro)     duloxetine (Cymbalta)     bupropion extended release (Wellbutrin XL)	See previo	us meeting:	s below in ta	able	See previous meetings below in table	See previous meetings below in table	No
A 09	Calcium Channel	Nisoldipine geomatrix (Sular geomatrix)	2,027	56	1,188	783	60	New drug in already reviewed class; low utilization	No
Aug 08	Channel Blockers	Original Meeting Aug 05  amlodipine (Norvasc)  Nov 07: removed from NF status  isradipine IR (Dynacirc)  isradipine ER (Dynacirc CR)	See previo	us meeting:	s below in ta	able	See previous meetings below in table	See previous meetings below in table	No

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	ciaries Affec	cted by	Implementation Plan	Justification	Step
Weeting	Class	Non-Formulary medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justilication	Therapy
		<ul> <li>nicardipine IR (Cardene, generics)</li> <li>nicardipine SR (Cardene SR)</li> <li>verapamil ER (Verelan)</li> <li>verapamil ER for bedtime dosing (Verelan PM, Covera HS)</li> <li>diltiazem ER for bedtime dosing (Cardizem LA)</li> </ul>							
Jun 08	Triptans	<ul><li>Almotriptan (Axert)</li><li>Frovatriptan (Frova)</li><li>Naratriptan (Amerge)</li></ul>	3,763	208	3,212	343	(26 Nov 2008) 90 days	Typical 90-day implementation period	No
Jun 08	Osteoporosis Agents	Salmon-calcitonin (Miacalcin)	2,914	945	1,948	1,021	(26 Nov 2008) 90 days	Typical 90-day implementation period	No
	Newer Antihistamines (NAs) (new drug in	Levocetirizine (Xyzal)	19,254	0	19,254	0	(29 Oct 2008) 60 days	New drug in already reviewed class	No
Jun 08	previously reviewed class); Original decision Aug 07	Original Meeting Aug 07  desloratadine (Clarinex) desloratadine/pseudoephed. (Clarinex D)	27,396	60	20,102	7,234	See previous meetings below in table	Typical 90-day implementation period	No
Jun 08	Leukotriene Modifiers (LMs (new drug in previously reviewed class);	Zileuton extended release (Zyflo CR)	288	0	288	0	(29 Oct 2008) 60 days	New drug in already reviewed class; low utilization	No
	Original decision Aug 07	Original Meeting Aug 07  zileuton (Zyflo)	144	4	110	31	See previous meetings below in table	Typical 90-day implementation period	No

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	iaries Affec	cted by	Implementation Plan	Justification	Step
Meeting	Class	Non-Formulary medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justilication	Therapy
	Beta Adrenergic Receptor Blockers (ABAs) (new drug in	Nebivolol (Bystolic)	2,462	0	2,462	0	(29 Oct 2008) 60 days	New drug in already reviewed class; low utilization	No
Jun 08	previously reviewed class); Original decision Nov 07	Original Meeting Nov 07 (No drugs designated non formulary)	0	0	0	0	See previous meetings below in table	No meds moved to non-formulary status	No
		ARB/CCB combos (Jun 08)  Olmesartan / amlodipine (Azor)	2,641	0	2,641	0	(29 Oct 2008) 60 days	New drug in already reviewed class with current low utilization	No
	Renin Antihypertensive Agents (RAAs) (new drug in previously reviewed class);	ARB/CCB combos (Nov 07)  valsartan / amlodipine (Exforge)	2,376	0	2,376	0	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No
Jun 08		ARBs – (May 07 meeting)  eprosartan (Teveten)  perosartan HCTZ (Teveten HCT)  irbesartan (Avapro)  irbesartan HCTZ (Avalide)  olmesartan (Benicar)  olmesartan HCTZ (Benicar HCT)  valsartan (Diovan)  valsartan HCTZ (Diovan HCT)  ACE/CCB combos – Feb 06 meeting  felodipine/enalapril (Lexxel)  verapamil/trandolapril (Tarka)  ACE Inhibitors (Aug 05 meeting)  moexipril (Univasc),  moexipril / HCTZ (Uniretic)  perindopril (Accon)  quinapril / ACCupril)  quinapril (Altace)	See previous meetings for affected beneficiaries for each subclass				See previous meetings below in table	See previous meetings below in table	

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	ciaries Affec	cted by	Implementation Plan	Justification	Step
weeting	Class	Non-Formulary medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justilication	Therapy
Nov 07	Benign Prostatic Hypertension (BPH) Alpha Blockers (ABs)	tamsulosin (Flomax)	64,783	1,426	40,161	23,196	(16 Apr 2008) 60-days	3 <sup>rd</sup> class for Step Therapy	Yes
Nov 07	Targeted Immuno- modulatory Biologics (TIBs)	<ul><li>etanercept (Enbrel)</li><li>anakinra (Kineret)</li></ul>	7,397	1,939	4,149	1,309	(18 Jun 2008) 90-days	Typical 90-day implementation period	No
Nov 07	Attention Deficit Hyperactivity Disorder (ADHD) / Narcolepsy agents (new drug in previously reviewed	lisdexamfetamine (Vyvanse)	2,200 Rxs	0	2,200 Rxs	0	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No
	class); Previous decision Nov 06	Original decision Nov 06  Dexmethylphenidate IR (Focalin) Dexmethylphenidate SODAS (Focalin XR) Methylphenidate transdermal patch (Daytrana)	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected	
Nov 07	Contraceptive Agents (new drug in previously reviewed class); Previous decisions May 06, Nov 06	EE 20 mcg / levonorgestrel 0.09 mg (Lybrel)	290 Rxs	2 Rxs	263 Rxs	25 Rxs	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No
		Previous meetings May 06 & Nov 06  EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale)  EE 25 mcg / norethindrone 0.4 mg (Ovcon 35)	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Seasonale, packaged as a 3- month supply; Loestrin 24 FE and Seasonique to coincide with	

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	ciaries Affec	cted by	Implementation Plan	Justification	Step
Meeting	Class	Non-Formulary medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justilication	Therapy
		<ul> <li>EE 50 mcg / norethindrone 1 mg (Ovcon 50)</li> <li>EE 20/30/35 mcg / norethindrone 1 mg (Estrostep Fe)</li> <li>EE 20 mcg/1 mg norethindrone- 24 day regimen (Loestrin 24 Fe)</li> <li>EE 30/10 mcg/ 0.15 mg levonorgestrel for</li> </ul>	Seasonique: 161 (from Apr 06-Oct 06)	0 Rxs	112 Rxs	4 Rxs		Seasonale decision	
		extended use (Seasonique)	Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)	22 Rxs	3,417 Rxs	64 Rxs			
Aug 07	Nasal Corticosteroid Agents (new drug in previously reviewed	Agents ew drug in usly reviewed class);	650	0	650	0	TMOP & TRRx: 60- days for current users; \$22 co-pay in effect immediately for new users MTF: No later than 60 days	New drug in already reviewed class with current low utilization	No
	Original decision Nov 05	Original Decision: Nov 05  beclomethasone dipropionate (Beconase AQ, Vancenase AQ)  budesonide (Rhinocort Aqua)  triamcinolone (Nasacort AQ)					19 Jan 06 (90 days)	Substantial number of beneficiaries	
Aug 07	Growth Stimulating Agents (GSAs)	<ul> <li>somatropin (Genotropin, Genotropin Miniquick)</li> <li>somatropin (Humatrope)</li> <li>somatropin (Omnitrope)</li> <li>somatropin (Saizen)</li> </ul>	653	77	310	266	TMOP & TRRx: 60- days for current users; MTF: No later than 60 days	Low number of affected beneficiaries affected	No
May 07	Antilipidemic II Agents (LIP-2s)	<ul> <li>fenofibrate nanocrystallized (Tricor)</li> <li>fenofibrate micronized (Antara)</li> <li>omega-3 fatty acids (Omacor)</li> <li>colesevelam (Welchol)</li> </ul>	83,612	18,849	44,402	20,361	24 Oct 07 (90 days)	Typical 90-day implementation period	No
May 07	5-Alpha Reductase Inhibitors (5-ARIs)	dutasteride (Avodart)	20,917	1,087	12,830	7,000	24 Oct 07 (90 days)	Typical 90-day implementation period	No

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	iaries Affec	cted by	Implementation Plan	Justification	Step
Weeting	Class	Non-i officially medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justilication	Therapy
May 07 (Update from Feb 05)	PPIs	<ul> <li>lansoprazole (Prevacid)</li> <li>omeprazole/sodium bicarbonate (Zegerid)</li> <li>pantoprazole (Protonix)</li> <li>rabeprazole (Aciphex)</li> </ul>	453,525	212,130	178,120	63,275	24 Oct 07 (90 days)	Typical 90-day implementation period	Yes
May 07 (Update from Feb 05)	ARBs	<ul> <li>eprosartan (Teveten)</li> <li>eprosartan HCTZ (Teveten HCT)</li> <li>irbesartan (Avapro)</li> <li>irbesartan HCTZ (Avalide)</li> <li>olmesartan (Benicar)</li> <li>olmesartan HCTZ (Benicar HCT)</li> <li>valsartan (Diovan)</li> <li>valsartan HCTZ (Diovan HCT)</li> </ul>	228,581	68,059	109,595	50,930	21 Nov 07 (120 days)	Reservations regarding ESI ability to handle implementation	No
Feb 07	Newer Sedative Hypnotics	<ul><li>Ramelteon (Rozerem)</li><li>Zaleplon (Sonata)</li><li>Zolpidem ER (Ambien CR)</li></ul>	40,447	5,878	31,550	3,019	1 Aug 07 (90 days)	First time automated PA with step edit	Yes
Feb 07	Narcotic Analgesics	Tramadol ER (Ultram ER)	1,088	0	46	1,042	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Feb 07	Glaucoma Agents	<ul> <li>Travoprost (Travatan, Travatan Z)</li> <li>Timolol maleate (Istalol)</li> <li>Timolol hemihydrate (Betimol)</li> <li>Brinzolamide (Azopt)</li> </ul>	17,139	1,735	12,267	3,117	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Feb 07	MAOI Antidepressants	Selegiline transdermal system (Emsam)	168	0	157	11	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Nov 06	ADHD	<ul> <li>Dexmethylphenidate IR (Focalin)</li> <li>Dexmethylphenidate SODAS (Focalin XR)</li> <li>Methylphenidate transdermal patch (Daytrana)</li> </ul>	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected	No
Nov 06	Older Sedative Hypnotics	-	0	0	0	0	18 Apr 07 (90 days)	No medications moved to non- formulary status	No
Aug 06	TZDs	-	0	0	0	0	Not applicable	No medications moved to non- formulary status	No

Maatina	Drug	Non Formulani Medicationa	Total Beneficiaries	Benefic	ciaries Affec	cted by	Implementation Plan	luctification	Step
Meeting	Class	Non-Formulary Medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justification	Therapy
Aug 06	H2 Antagonists / GI protectants	-	0	0	0	0	Not applicable	No medications moved to non- formulary status	No
Aug 06	Antilipidemic I Agents	<ul><li>Rosuvastatin (Crestor)</li><li>Atorvastatin / amlodipine (Caduet)</li></ul>	44,078	851	36,133	6,921	1 Feb 07 (90 days)	Small number of beneficiaries affected	No
May 06	Antiemetics	Dolasetron (Anzemet)	852	14	668	170	27 Sept 06 (60 days)	Small number of beneficiaries affected, and acute nature of treatment (e.g., chemotherapy)	No
May 06 update for new drugs	Contraceptive Agents	Original Decision May 06  EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale)  EE 25 mcg / norethindrone 0.4 mg (Ovcon 35)  EE 50 mcg / norethindrone 1 mg (Ovcon 50)  EE 20/30/35 mcg / norethindrone 1 mg (Estrostep Fe)	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Relatively low number of beneficiaries affected, but a high proportion are receiving Seasonale, which is packaged as a 3-month supply	No
Nov 06		Nov 06  EE 20 mcg/1 mg norethindrone- 24 day regimen (Loestrin 24 Fe)  EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique)	Seasonique 161 (from Apr 06-Oct 06)	0 Rxs	112 Rxs	4 Rxs	Jan 24 07	Small number of	
			Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)	22 Rxs	3,417 Rxs	64 Rxs	(60 days; to coincide with Seasonal)	beneficiaries affected	No

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	iaries Affe	cted by	Implementation Plan	Justification	Step
weeting	Class	Non-Formulary Medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justilication	Therapy
Feb 06	OABs	tolterodine IR (Detrol)     oxybutynin patch (Oxytrol)     trospium (Sanctura)	19,118	2,596	13,471	3,051	26 July 06 (90 days)	Recommended 60- day implementation overturned; 90-day BAP recommendation accepted	No
Feb 06	Misc Anti- hypertensive Agents	felodipine/enalapril (Lexxel) verapamil/trandolapril (Tarka)	5,946	336	4,472	1,138	26 July 06 (90 days)	Recommended 60- day implementation overturned; 90-day BAP recommendation accepted	No
Feb 06	GABA-analogs	pregabalin (Lyrica)	30,649	1,120	27,566	1,963	28 Jun 06 (60 days)	Small number of beneficiaries affected	No
Nov 05	Alzheimer's Drugs	tacrine (Cognex)	5	0	3	2	19 Apr 06 (90 days)	Small number of beneficiaries affected	No
Nov 05	Nasal Corticosteroid Agents	<ul> <li>beclomethasone dipropionate (Beconase AQ, Vancenase AQ)</li> <li>budesonide (Rhinocort Aqua)</li> <li>triamcinolone (Nasacort AQ)</li> </ul>	96,999	13,556	73,381	10,062	19 Apr 06 (90 days)	Substantial number of beneficiaries affected	No
Nov 05	Macrolide/ Ketolide Antibiotics	azithromycin 2 gm (Zmax)     telithromycin (Ketek)	Total number not provided; antibiotics are used to treat acute infections				22 Mar 06 (60 days)	Small number of beneficiaries affected, Medication used to treat acute (not chronic) infections not likely to require therapy change	No
Nov 05	Antidepressants I	<ul> <li>paroxetine HCl CR (Paxil)</li> <li>fluoxetine 90 mg for weekly administration (Prozac Weekly)</li> <li>fluoxetine in special packaging for PMDD (Sarafem)</li> <li>escitalopram (Lexapro)</li> <li>duloxetine (Cymbalta)</li> <li>bupropion extended release (Wellbutrin XL)</li> </ul>	182,916	52,624	118,582	11,710	19 Jul 06 (180 days)	Substantial number of beneficiaries affected	No

Meeting	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	iaries Affe	cted by	Implementation Plan	latification	Step
weeting	Class	Non-Formulary Medications	Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date	Justilication	Therapy
Aug 05	Alpha Blockers for BPH	tamsulosin (Flomax)	89,926	26,692	47,674	15,560	15 Feb 06 (120 days)	Substantial number of beneficiaries affected	No
Aug 05	CCBs	amlodipine (Norvasc)         Nov 07: amlodipine removed from NF status     isradipine IR (Dynacirc)     isradipine ER (Dynacirc CR)     nicardipine IR (Cardene, generics)     nicardipine SR (Cardene SR)     verapamil ER (Verelan)     verapamil ER for bedtime dosing (Verelan PM, Covera HS)     diltiazem ER for bedtime dosing (Cardizem LA)	274,616	133,794	101,345	39,477	15 Mar 06 (150 days)	Substantial number of beneficiaries affected	No
Aug 05	ACE Inhibitors & ACE Inhibitor / HCTZ Combinations	<ul> <li>moexipril (Univasc),</li> <li>moexipril / HCTZ (Uniretic)</li> <li>perindopril (Aceon)</li> <li>quinapril (Accupril)</li> <li>quinapril / HCTZ (Accuretic)</li> <li>ramipril (Altace)</li> </ul>	158,101	77,159	57,982	22,959	16 Feb 06 (120 days)	Substantial number of beneficiaries affected	No
May 05	PDE-5 Inhibitors	sildenafil (Viagra)     tadalafil (Cialis)	128,007	55,161	49,850	22,996	12 Oct 05 (90 days)	Substantial number of beneficiaries affected	No
May 05 updated for new	Topical Antifungals*	<ul> <li>econazole</li> <li>ciclopirox</li> <li>oxiconazole (Oxistat)</li> <li>sertaconazole (Ertaczo)</li> <li>sulconazole (Exelderm)</li> </ul>	49,743	14,266	33,430	2,047	17 Aug 05 (30 days)	Medication used to treat acute (not chronic) infections not likely to require therapy change	No
drug Nov 06		<ul> <li>miconazole 0.25%, zinc oxide 15%, white petrolatum 82.35% (Vusion)</li> </ul>	581 (Apr 06-Oct 06) (UU not applicable)	7	571	3	21 Feb 07 (60 days)	Small numbers of beneficiaries affected	No
May 05	MS-DMDs	-	0	0	0	0	Not applicable	No medications moved to non- formulary status	No

	Drug	Non-Formulary Medications	Total Beneficiaries	Benefic	ciaries Affec	cted by	Implementation Plan	Justification	Step
	Class		Affected (# of patients affected)	MTF	Retail	Mail Order	First Wednesday X days after the decision date		Therapy
Feb 05	ARBs	<ul><li>eprosartan (Teveten)</li><li>eprosartan/HCTZ (Teveten HCT)</li></ul>	2,184	13	1,644	527	17 Jul 05 (90 days)	Recommended 30- day implementation overturned; 90-day BAP recommendation accepted	No
Feb 05	PPIs	esomeprazole (Nexium)	138,739	6,691	117,520	14,528	17 Jul 05 (90 days)	Substantial number of beneficiaries affected	

BCF = Basic Core Formulary; ECF = Extended Core Formulary; ESI = Express-Scripts, Inc; MN = Medical Necessity; TMOP = TRICARE Mail Order Pharmacy; TRRx = TRICARE Retail Pharmacy program; UF = Uniform Formulary

CR = controlled release; ER = extended release; IR = immediate release; LA = long-acting; SR = sustained release; XL = extended release

5-ARI = 5-Alpha Reductase Inhibitors; ADHD = Attention Deficit Hyperactivity Disorder; ACE Inhibitors = Angiotensin Converting Enzyme Inhibitors; ARBs = Angiotensin Receptor Blockers; BPH = Benign Prostatic Hypertrophy; CCBs = Calcium Channel Blockers; EE = ethinyl estradiol; GSAs = Growth Stimulating Agents; GI = gastrointestinal; GABA = gamma-aminobutyric acid; H2 = Histamine-2 receptor; HCTZ = hydrochlorothiazide; Leukotriene Modifiers = LMs; LIP-1s = Antilipidemic I; LIP-2s = Antilipidemic II; MAOI = Monoamine Oxidase Inhibitor; MS-DMDs = Multiple Sclerosis Disease-Modifying Drugs; NAs = Newer Antihistamines; OABs = Overactive Bladder Medications;

PDE-5 Inhibitors = Phosphodiesterase-5 inhibitors; PMDD = Premenstrual Dysmorphic Disorder; PPIs = Proton Pump Inhibitors; RAAs = Renin Antihypertensive Agents; SODAS = spheroidal oral drug absorption system; TZDs = thiazolidinediones

\*The topical antifungal drug class excludes vaginal products and products for onychomycosis (e.g., ciclopirox topical solution [Penlac])